Toggle Main Menu Toggle Search

Open Access padlockePrints

A Novel α-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease

Lookup NU author(s): Professor Tiago OuteiroORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Background: Parkinson's disease (PD) is a complex multifactorial disorder with a genetic component in about 15% of cases. Multiplications and point mutations in SNCA gene, encoding α-synuclein (aSyn), are linked to rare familial forms of PD. Objective: Our goal was to assess the clinical presentation and the biological effects of a novel K58N aSyn mutation identified in a patient with PD. Methods: We describe the clinical presentation associated with the novel mutation, together with genetic testing through whole exome sequencing (WES). Furthermore, we conducted extensive biophysical and cellular assays to assess the functional consequences of this novel variant. Results: The patient exhibited typical features of sporadic PD with early onset and a benign disease course. WES showed a novel heterozygous missense variant in SNCA (NM_000345.4, c.174G>C; p.K58N). A positive family history of PD was evident, because both a parent and a grandparent had been diagnosed with PD but were deceased. The patient underwent deep brain stimulation surgery 13 years postdiagnosis, showing stable, long-term improvements in motor symptoms. Biophysical studies demonstrated K58N substitution causes local structural effects, disrupts membrane binding, and enhances aSyn in vitro aggregation. In cellular systems, K58N aSyn produces fewer inclusions per cell and does not form condensates. The variant increases aSyn cytoplasmic distribution and displays aberrant activity-dependent dynamic serine-129 phosphorylation. Conclusions: The clinical presentation associated with the novel K58N aSyn mutation suggests a relatively benign PD course consistent with the phenotypic spectrum of idiopathic PD. Overall, our molecular studies provide novel insight into the biology and pathobiology of aSyn. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


Publication metadata

Author(s): Al-Azzani M, Weber S, Ramalingam N, Ramon M, Shvachiy L, Mestre G, Zech M, Sicking K, de Opakua AI, Jayanthi V, Amaral L, Agarwal A, Chandran A, Chaves SR, Winkelmann J, Trenkwalder C, Schwager M, Pauli S, Dettmer U, Fernandez CO, Lautenschlager J, Zweckstetter M, Busnadiego RF, Mollenhauer B, Outeiro TF

Publication type: Article

Publication status: Published

Journal: Movement Disorders

Year: 2025

Pages: Epub ahead of print

Online publication date: 04/09/2025

Acceptance date: 15/08/2025

Date deposited: 16/09/2025

ISSN (print): 0885-3185

ISSN (electronic): 1531-8257

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/mds.70030

DOI: 10.1002/mds.70030

Data Access Statement: The main data generated or analyzed during this study are included in this article (and its Supporting Information files). The micrographs used for the single-particle analysis (SPA) of aSyn fibrils are available in the EMPIAR database under accession code EMPIAR-12518. The atomic model and cryo-EM density map for the WT aSyn fibril are deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under accession codes 9HGS and EMD-52165, respectively. The corresponding data for the K58N mutant aSyn fibril are available under accession codes 9HXA (PDB) and EMD-52458 (EMDB). A comprehensive Key Resource Table, detailing datasets, software, and protocols, is available via Zenodo at: https://zenodo.org/records/14730688. [See the article for the full Data Availability Statement.]


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy (EXC 2067/1–390729940)
SFB1286 (B8)

Share